Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants

Vaccine

Volumn 26, Issue 40, 2008, Pages 5196-5201

  Palma, Paolo ^a,b   Romiti, Maria Luisa ^a   Cancrini, Caterina ^a,b   Pensieroso, Simone ^a   Montesano, Carla ^a   Bernardi, Stefania ^b   Amicosante, Massimo ^a   Di Cesare, Silvia ^a   Castelli Gattinara, Guido ^b   Wahren, Britta ^c   Rossi, Paolo ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HIV infected infants; HIV specific immune response; Timing of treatment

Indexed keywords

ABACAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; STAVUDINE; T LYMPHOCYTE RECEPTOR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREACTIVITY; INFANT; LIPODYSTROPHY; LYMPHOCYTE PROLIFERATION; PRESCHOOL CHILD; PRIORITY JOURNAL; T LYMPHOCYTE; THERAPY DELAY; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PEPTIDES; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 50849137826     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.062     Document Type: Article

References (29)

1. Aboulker J.P., Babiker A., Chaix M.L., Compagnucci A., Darbyshire J., Debre M., et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 18 (2004) 237-245
2. Luzuriaga K., McManus M., Mofenson L., Britto P., Grahem B., and Sullivan J.L. PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 350 (2004) 2471-2480
3. Dunn D., and HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362 (2003) 1605-1611
4. Faye A., Le Chenadec J., Dollfus C., Thuret I., Douard D., Firtion G., et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis (2004) 1692-1698
5. Verweel G., Saavedra-Lozano J., van Rossum A., Ramilo O., and de Groot R. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States. Pediatr Infect Dis J 25 (2006) 987-994
6. Chiappini E., Galli L., Tovo P.A., Gabiano C., Gattinara G., Guarino A., et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS 20 (2006) 207-215
7. Hainaut M., Peltier C.A., Gerard M., Marissens D., Zissis G., and Levy J. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr 159 (2000) 778-782
8. Romiti M.L., Cancrini C., Castelli-Gattinara G., Di Cesare S., Ciuffi P., Bernardi S., et al. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART. AIDS 15 (2001) 2075-2084
9. Faye A., Bertone C., Teglas J.P., Chaix M.L., Douard D., Firtion G., et al. French Perinatal Study. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 21 (2002) 518-525
10. Abrams E.J., and Kuhn L. Should treatment be started among all HIV-infected children and then stopped?. Lancet 62 (2003) 1595-1596
11. Scott Z.A., Chadwick E.G., Gibson L.L., Catalina M.D., McManus M.M., Yogev R., et al. Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific. CD8(+) T cell responses in young HIV-1-infected infants. J Immunol 167 (2001) 7134-7140
12. Spiegel H.M., De Falcon E., Ogg G.S., Sheehy M.E., Monard S., Haslett P.A., et al. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis 180 (1999) 359-368
13. Borkowsky W., Zhan M.X., Chen S.H., Ilmet T., Kaul A., Chandwani S., et al. Correlation between HIV-specific CD8 cell production of interferon-gamma and plasma levels of HIV RNA in perinatally infected pediatric populations. J Infect Dis 190 (2004) 722-726
14. Luzuriaga K., McManus M., Catalina M., Mayack S., Sharkey M., Stevenson M., et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 74 (2000) 6984-6991
15. Viganò A., Trabattoni D., Schneider L., Ottavini F., Aliffi A., Longhi E., et al. Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. J Pediatr 148 (2006) 389-391
16. Ching N., Yang O., Deville J.G., Nielsen-Saines K., Ank B.J., Sim M.S., et al. Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy. Pediatr Res 61 (2007) 692-697
17. Zanchetta M., Anselmi A., Vendrame D., Rampon O., Giaquinto C., Mazza A., et al. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther 13 1 (2008) 47-55
18. Feeney M.E., Draenert R., Roosevelt K.A., Pelton S.I., McIntosh K., Burchett S.K., et al. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol 171 (2003) 6968-6975
19. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., et al. HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278 (1997) 1447-1450
20. Maslanka K., Piatek T., Gorski J., Yassai M., and Gorski J. Molecular analysis of T cell repertoires. Spectratypes generated by multiplex polymerase chain reaction and evaluated by radioactivity or fluorescence. Hum Immunol 44 1 (1995) 28-34
21. Amicosante M., Gioia C., Montesano C., Casetti R., Topino S., D'Offizi G., et al. Computer-based design of an HLA haplotype and HIV-clade independent cytotoxic T-lymphocyte assay for monitoring HIV-specific immunity. Mol Med 8 (2002) 798-807
22. Sharland M., Blanche S., Castelli G., Ramos J., Gibb D.M., and PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy. HIV Med 5 Suppl. 2 (2004) 61-86
23. Luzuriaga K., Wu H., McManus M., Britto P., Borkowsky W., Burchett S., et al. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol 73 (1999) 362-367
24. Shearer W.T., Rosenblatt H.M., Gelman R.S., Oyomopito R., Plaeger S., Stiehm E.R., et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 112 (2003) 973-980
25. Buseyne F., Scott-Algara D., Bellal N., Burgard M., Rouzioux C., Blanche S., et al. The frequency of HIV-specific interferongamma-producing CD8 T cells is associated with both age and level of antigenic stimulation in HIV-1-infected children. J Infect Dis 192 10 (2005) 1781-1786
26. Younes S.A., Trautmann L., Yassine-Diab B., Kalfayan L.H., Kernaleguen A.E., Cameron T.O., et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol 178 2 (2007) 788-797
27. Kou Z.C., Puhr J.S., Wu S.S., Goodenow M.M., and Sleasman J.W. Combination antiretroviral therapy results in a rapid increase in T cell receptor variable region beta repertoire diversity within CD45RA CD8 T cells in human immunodeficiency virus-infected children. J Infect Dis 187 (2003) 385-397
28. Sandberg J.K., Fast N.M., Jordan K.A., Furlan S.N., Barbour J.D., Fennelly G., et al. HIV-specific CD8+ T cell function in children with vertically acquired HIV-1. Infection is critically influenced by age and the state of the CD4+ T cell compartment. J Immunol 170 (2003) 4403-4410
29. Palma P., Romiti M.L., Cancrini C., Pensieroso S., Montesano C., Santucci M.B., et al. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in HIV-1 vertically infected children. AIDS 21 (2007) 2465-2472